FDA inspection
Shield Technology Corporation: FDA inspection ending Jan 6, 2000
FDA inspection 1691 · Official Action Indicated (OAI) · New Orleans, LA
Key facts
| Inspection ID | 1691 |
|---|---|
| Firm | Shield Technology Corporation |
| FEI number | 3002838807 |
| Address | 1069 S Jefferson Davis Pkwy |
| City | New Orleans |
| State | LA |
| ZIP | 70125-1235 |
| Fiscal year | 2000 |
| Inspection end date | Jan 6, 2000 |
| Classification | Official Action Indicated (OAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs |
| Product type | Drugs |
| Warning letter | UCM068246 |
At a glance
- None Citations
- 1–9 Posted citations
- Yes Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data